The GLP-1 agonist at the center of Pfizer’s upfront $4.9 billion buyout of Metsera last week has been tied to 14.1% weight loss at 28 weeks as well as “potentially class-leading tolerability,” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback